p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 10, 1997, Pages 565-570

  Sengelov L ^a   Horn, T ^a   Steven, K ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bladder cancer; p53; Prognostic factors

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BONE NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0030783796     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050106     Document Type: Article

References (24)

1. Bartkova J, Bartek J, Vojtesek B, Lukas J, Rejthar A, Kovarik J, Millis RR, Lane DP, Barnes DM (1993) Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumors. Eur J Cancer 29A:881-886
2. Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, Cohen AM (1996) p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastasis. J Clin Oncol 14:2696-2701
3. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A (1994) p53 mutations in human bladder cancer: Genotypic versus phenotypic pattern. Int J Cancer 56:347-353
4. Cox D (1972) Regression models and life tables. J R Statist Soc B 34:187-220
5. Daidone MG, Benini E, Valentinis B, Tomasic G, Bolis G, Villa A, Silvestrini R (1996) p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial stromal tumors. Eur J Cancer 32A: 1388-1393
6. Dalbagni G, Presti J, Reuter V, Fair W, Cordon-Cardo C (1993) Genetic alterations in bladder cancer. Lancet 342:469-471
7. Esrig D, Spruck CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389-1397
8. Esrig D, Elmajiun D, Groshen S, Freeman JA, Stein JP, Chen S, Nichols PW, Skinner DG, Jones PA, Cote RJ (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259-1264
9. Geertsen PF, Sengeløv L, Larsen SK, von der Maase H (1993) A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium. Eur J Cancer 29A:347-350
10. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457-481
11. Kuczyk MA, Bokemeyer C, Serth J, Hervatin C, Oelke M, Höfner K, Tan HK, Jonas U (1995) p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 31 A:2243-2247
12. Lane DP (1994) The regulation of p53 function. Steiner award lecture. Int J Cancer 57:623-627
13. Lipponen PK (1993) Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 53:365-370
14. Lowe SC (1995) Cancer therapy and P53. Curr Opin Oncol 7:547-553
15. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) P53 status and the efficacy of cancer therapy in vivo. Science 266:807-810
16. Meyn RE, Stephens LC, Mason KA, Medina D (1996) Radiation-induced apoptosis in normal and pre-neoplastic mammry glands in vivo: significance of gland differentiation and p53 status. Int J Cancer 65:466-472
17. Olumi AF, Skinner EC, Tsai YC, Jones PA (1990) Molecular analysis of human bladder cancer. Semin Urol 8:270-277
18. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang Z, Schultz PK, Cardon-Cardo C, Scher HI (1995) Prognostic value of p53 Nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 13:1384-1390
19. Sengeløv L, Nielsen OS, Kamby C, Maase H von der (1995) Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methorexate in patients with metastatic urothelial tract tumors. Cancer 76:1797-1803
20. Spruck CH, Ohneseit PF, Gonzales-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmütte C, Yang AS, Cote R, Du beau L, Nichols PW, Hermann GO, Steven K, Horn T, Skinner DG, Jones PA (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784-788
21. Vet JAM, Bringuier PP, Poddighe PJ, Karthaus HFM, Debruyne FMJ, Schalken JA (1994) p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 70:496-500
22. Vet JAM, Bringuier PP, Schaafsma HE, Witjes JA, Debruyne FMJ, Schalken JA (1995) Comparison of p53 protein overexpression with p53 mutation in bladder cancer: clinical and biological aspects. Li 73:837-843
23. Waldman T, Lengauer C, Kinzler KW, Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713-716
24. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO Offset Publication